A mRNA levels for endogenous MDM2 and CDKN1A in response to treatment with or without 10 lM Nutlin-3. Error bars = SEM (n = 2). B
Western blot of p53-Venus levels in the MDM2 promoter reporter cell line untreated or treated with 400 ng/ll neocarzinostatin (NCS), 5 lM Nutlin-3, 10 lM Nutlin-3, or 15 lM Nutlin-3 for 3 h. C-L p53-Venus expression in response to the low-amplitude (C, D), high-amplitude (E, F), high-frequency (G, H), low-frequency/short-duration (I, J), and long-duration (K, L) Nutlin-3 dosing regimens. Single-cell traces (gray) and the mean (red) are shown in (C, E, G, I, K) for p53-Venus expression in response to each Nutlin-3 regimen. Heat maps (D, F, H, J, L) shown as alternative representations of all traces as shown in (E) . N = at least 45 cells per condition. M p53-Venus levels integrated over 24 h for cell lines with or without the MDM2 promoter reporter exposed to Nutlin-3 treatment. Line = mean, box = SD, bar = 95% confidence interval (N = at least 45 cells).
Source data are available online for this figure. A Schematic for comparing the rate of target promoter activation when p53 is at comparable cumulative levels in response to duration-and frequency-modulated p53 inputs. Rates were calculated between the time of the first p53 pulse peak (t peak ) and the time at which the cumulative p53 levels are equal plus an additional 5.5 h (t X + s), where s = 5.5 h is the natural p53 pulse period. B, C Activation rates of the MDM2 (B) and CDKN1A (C) promoters at times of equivalent cumulative p53 levels in response to temporal pulse modulations. Line = mean, box = SD, bar = 95% confidence interval (N = at least 45 cells). **P < 0.01, two-sample t-test. 
